Quantcast

Latest Piperazines Stories

2014-03-13 04:23:04

TAIPEI, March 13, 2014 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that the Taiwan Food and Drug Administration (TFDA) has approved the new drug application (NDA) of Taigexyn(® )(nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn(®). An NDA for Taigexyn(® ) was also submitted to China FDA (CFDA) in...

2014-03-03 23:21:45

Transparency Market Research adds new "Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" market research report to its report store. Browse the report with request TOC; visit http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html Albany, NY (PRWEB) March 03, 2014 According to a new market report published by...

2014-02-26 16:26:01

DUBLIN, February 26, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/khhjl8/erectile) has announced the addition of the "Erectile Dysfunction Drugs Market - Forecast to 2019" [http://www.researchandmarkets.com/research/khhjl8/erectile ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the...

2014-02-24 08:29:21

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2014 /PRNewswire/ -- Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics in cancer, today announced the commencement of patient dosing in its first Phase 1 study of CB-839 in patients with advanced solid tumors. CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that interferes with tumor metabolism and blocks cancer cell growth and...

2014-02-20 23:23:30

Drug Allegedly Linked to Serious Muscle Problems and Nerve Damage Dallas, TX (PRWEB) February 20, 2014 The national law firm of Baron and Budd is now representing clients filing lawsuits against the maker of Cipro, an antibiotic that has been allegedly linked to nerve damage and peripheral neuropathy. This is a muscle condition that can lead to several problems, including difficulty walking, significant pain and arm and leg numbness. Cipro, the brand name for the drug ciprofloxacin, is...

2014-02-20 23:01:06

Antibiotic Allegedly Associated With Severe Nerve and Muscle Problems Dallas, TX (PRWEB) February 20, 2014 Baron and Budd, a national plaintiffs’ law firm, announced today that it is accepting lawsuits against the manufacturers of Levaquin, an antibiotic designed to treat bacterial illnesses and infections. The medication has been allegedly linked to a serious condition known as peripheral neuropathy, which can result in several types of sensory problems such as pain, diminished...

2014-02-12 08:28:26

- BL-8040 study published in Molecular Cancer Therapeutics - JERUSALEM, Feb. 12, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive pre-clinical results for BL-8040 in a third indication - as a treatment for chronic myeloid leukemia. Results of the study were recently published in Molecular Cancer Therapeutics. (Logo:...

2014-02-11 16:25:38

First liquid formulation clozapine for treatment-resistant schizophrenia DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz(TM) (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. "We are pleased to offer patients with...

2014-02-11 08:31:56

Agency Proposes Select Phase I Studies as Part of Resubmission RALEIGH, N.C., Feb. 11, 2014 /PRNewswire/ -- Sprout Pharmaceuticals announced today that their Formal Dispute Resolution, which was filed in December 2013, resulted in clear guidance from the FDA on the path forward. Sprout will resubmit the New Drug Application (NDA) for flibanserin, a once-daily treatment for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women, by the third quarter. The FDA has requested...

2014-02-05 12:28:03

Over 400 subjects participating in phase 3 studies PINE BROOK, N.J., Feb. 5, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed enrollment in three phase 3 safety studies of ETI-204, an anti-toxin in development for the treatment of inhalational anthrax. Elusys also announced it has completed enrollment in an additional study to evaluate the tolerability...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'